niafrederiksenii, Yersinia kristensenii, and Yersinia.iintermedia, have been considered enterically avirulent in humans (3, 5, 30) . Yersiniae have been shown to have toxigenic properties and cellular adhesion factors that are associated with plasmid carriage (16, 23) .
Virulence of Yersinia species in humans has been associated with a number of in vivo and in vitro bacterial characteristics, including deep organ infiltration in orally inoculated mice (1) , dependence on calcium for growth (11) , ability to absorb a hemin-type dye, Congo red (24) , and carriage of a 40-to 48-megadalton plasmid (31) . Each characteristic has some reliability in identifying organisms with potential virulencé in humans (25) , but none considers the human response to the organism.
Several recent studies have documented a rise in serum titér of Yersinia-specific antibody early in infection (8, 9, 15) , primarily accounted for by immunoglobulin A (IgA) class antibodies, in particular the 11S or dimer form normally found in secretions (8) . Since methods for detecting IgA in serum are not entirely reliable (15) and no criteria exist for ascribing significance to an increased IgA titer (4) , the diagnostic applications of serum IgA levels are limited. In addition, serological analysis, either by agglutination or by enzyme-linked immunosorbent assay, requires a second postillness specimen that is not generally readily available.
In 1971, Reed and Williams (26) documented the presence of secretory IgA (SIgA) class Shigella-agglutinating antibodies in feces from patients with recent-onset diarrhea. Although no mechanistic role was suggested, a good correla-* Corresponding author. tion between coproantibody production and stage of enteric illness was clearly demonstrated. A number of investigators have since reported coproantibody responses to enteric organisms in rectal mucosa and feces by using indirect immunofluorescence assays (6, 7, 21) .
This study observes that a semiquantitative indirect immunofluorescence assay can determine human intestinal immune response to Yersinia species and compares this response with both in vivo and in vitro virulence-associated characteristics and human disease presentation.
MATERIALS AND METHODS
Specimens and organisms. Fecal specimens were received in the microbiology laboratory of the university hospital în Cary-Blair transport medium or sterile containers and proël-essed as described previously (22) . Fecal samples were maintained at -4°C until bacteriology, including cold entichment, was completed. When a yersinia strain was recovered, the clinical history of the patient was reviewed and the feéés wete processed for coproantibody SIgA determination. Crganismns were maintained at -70°C in glycerol and dimethyl sulfoxide until assayed for virulence.
Virulence-associated in vitro assays. Before organisnis were tested for virulence-associated characteristics, they were retrieved and transferred three times at 25°C on blQod agar plates (PML Microbiologicals). The virulence assays performed included calcium dependence (12) , Congo red absorption (24) , plasmid profiling (19) , autoagglutination (14) , and mouse virulence (1) . The first three assays were performed as described previously (22 Figure 1 demonstrates typical fluorescence microscope fields for a 2+, a 1+, a negative, and a negative in-phase response. A 2+ result is defined as large clusters of agglutinating organisms fluorescing bright apple green and is indicative of a strong specific IgA class antibody response ( (Fig. 1B) . When the cultured Yersinia species stimulated no antibody response, the field was apparently empty (Fig. 1C) . This absence of fluorescence cannot be accounted for by an absence of bacteria, as organisms were detected in phase contrast of the same field (Fig. 1D) . Supernatant-only and organism-only control slides showed some homogeneous background fluorescence, but no organismlike structures.
Fecal supernatants from diarrheic patients infected with Salmonella species (patients 29 to 31), Campylobacter species (patients 32 to 37), Clostridium species (patient 38), Shigella species (patient 39), or Escherichia coli (patient 40), and from asymptomatic, pathogen-negative patients (patients 41 to 43) were examined for cross-reactive agglutination with yersiniae. No specific agglutinating cross-reactivity was found; however, some nonagglutinating halo-type staining of single organisms similar to the 1+ reaction described above was detected when supernatants were tested against these control organisms. Therefore, for the purpose of interpretation, an agglutinating reaction was considered essential for positivity in the SIgA assay. Table 1 Y. frederiksenii, Y. kristensenii, and Y. intermedia were originally associated only with skin and wound infections or found as environmental isolates (3, 5, 30) ; however, they have been recovered from a number of patients presenting with acute diarrhea (22, 27) . Prpic et al. (25) found that some Y. enterocolitica-like organisms expressed some of the in vitro virulence-associated characteristics but were still avirulent in mice. This study also documents the expression of one or more in vitro virulence-associated characteristics in Y. frederiksenii and Y. kristensenii species. In addition, the existence of Y. frederiksenii and atypical Y. enterocolitica strains which are mouse virulent and immunostimulatory in humans was observed. This is consistent with our clinical observation that strains of Y. enterocolitica other than 0:3, 0:5,27, etc., may be pathogenic in humans. In addition, 58.3% of the mouse-virulent, antibody-inducing yersiniae were recovered only after cold enrichment (four recovered after 7 days, three recovered after 14 days), further supporting the importance of cold enrichment in the recovery of some enterically pathogenic yersiniae (22) .
SIgA is the best suited of the immunoglobulin to deal with antigenic material in the gut lumen, as it resists proteolysis by intestinal enzymes, has an affinity for the mucosa, and is the predominant immunoglobulin produced in the gut-associated lymphoid tissue in humans (19) . As it can both agglutinate organisms and prevent their adherence, SIgA is thought to be the most important resistance mechanism for bacterial elimination from the intestine (28) .
The existence of coproantibody SIgA in fecal specimens following enteric infections was documented as early as 1947, when Harrison and Banvard (11) reported the detection of agglutinating antibody in fecal specimens from patients with both acute and chronic bacillary dysentery. Since then several studies have reported the presence of high coproantibody titers in the feces (2) and intestinal mucosa (21) of patients with ulcerative colitis and in volunteers orally immunized with live Salmonella typhi vaccine (6, 7).
In the current investigation, the presence of high SIgA titers in fecal specimens has been clearly associated with acute enteric illness and carriage of mouse-virulent organisms. Of note, when patients with inflammatory bowel disease were excluded because their underlying illness created confounding data, the P.P. of SIgA for mouse virulence and acute enteric disease became 100%. In addition, this association was not found to be dependent on which species of Yersinia was isolated.
In 1951, Barksdale et al. (2) noted that certain strains of coliform bacilli contain antigenic components common to certain Shigella and Salmonella species. Such cross-reactions could conceivably limit the diagnostic value of a coproantibody assay, and therefore appropriate controls were included in this study. Since specimens from patients who are culture negative or positive for an enteropathogen, i.e., Salmonella species, Campylobacterjejuni, Clostridium difficile, Shigella sonnei, or E. coli, were negative, an agglutinating (2+) SIgA response appeared to be Yersinia specific. However, as the number of controls was low, no overall specificity could be determined.
Two exceptions to the association between SIgA response, acute disease, and mouse virulence in the current study were found in patients with Crohn's disease and acute colitis, both of whom exhibited a strong SIgA response to an apparently avirulent Yersinia strain. This was consistent with the findings of Barksdale et al. (2), who reported a patient with chronic ulcerative colitis from whom neither Shigella nor Salmonella organisms were isolated, yet whose coproantibodies agglutinated three Salmonella species and four or more Shigella species. Toivanen et al. (29) suggested that the persistence of yersiniae within the intestine, i.e., in epithelial or lymphoid tissues, could provide a stimulus for prolonged antibody production in cases of reactive arthritis. Such a mechanism may also be involved in maintenance of antibody production in inflammatory bowel disease. Monteiro et al. (21) suggested that strains of enteric bacteria which would produce only transient reactions in noncolitic patients may be able to elicit antibody production in mucosa of colitic patients. Further explanations include the possibility that a mouse-virulent organism could lose its temperature-dependent virulence plasmid while in the gut lumen or that strains of yersiniae may exist which are immunostimulatory in humans yet inactive in the mouse model. The latter is supported by the documentation by Hancock et al. of mice naturally resistant to some yersiniae (10 A number of patients who were culture positive for a mouse-virulent Yersinia strain carried a parasite, i.e., Blastocystis hominis or Dientamoeba fragilis. These patients may represent concurrent Yersinia and parasite infection, or infection with one organism predisposing the patient to the other; however, the sequence of infection could not be determined from a single fecal specimen. In these cases, the coproantibody SIgA assay may be of use in differentiating transient nonimmunostimulatory Yersinia isolates from those eliciting a strong intestinal immune response.
Since the majority of SIgA-positive patients presented only with acute short-lived enteric illness, sequential stool specimens were not always available. However, in two cases that were followed, patients 3 and 6, the reaction changed from 2+ to 1 + as the stool changed from fluid to formed and the symptoms disappeared. This appears to support the relationship between SIgA and acuteness of disease in humans.
In summary, a reproducible semiquantitative indirect immunofluorescence assay has been established which facilitates the performance of a serological assay for enteric yersiniosis with a single fecal specimen. A positive SIgA response predicted acute enteric illness and mouse virulence better than any of the established in vitro virulence-associated assays. ACKNOWLEDGMENTS This work was supported by a grant from the British Columbia Health Care Research Foundation (5-52403).
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